MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Stock
NASDAQ · MLTX
Key stats
- Market cap
- $1.15B
- Price / Earnings ratio
- -3.9x
- EPS (TTM)
- -$3.67
- Volume
- Loading
- 52-week high
- $23.29
- 52-week low
- $9.46
Source: third-party data provider, as of November 13, 2026
Compare with MLTX
Recent news

Stocktwits
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MLTXNovember 11, 2026
Stocktwits
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MLTX

Stocktwits
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTXSeptember 11, 2026
Stocktwits
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX

Reuters
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MLTXAugust 10, 2026
Reuters
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MLTX

Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MLTXAugust 3, 2026
Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MLTX
Technical indicators
- RSI 14
- 63.33
- MACD 12/26/9
- 0.19
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.25
- SMA 50
- $11.98
- Price above SMA 50
- EMA 50
- $12.51
- Price above EMA 50
- SMA 200
- $16.29
- Price below SMA 200
- EMA 200
- $14.89
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Strong Sell0
Sell0
Hold0
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
632M417M209M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-230.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MLTXNovember 11, 2026
Stocktwits
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MLTX

Stocktwits
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTXSeptember 11, 2026
Stocktwits
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX

Reuters
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MLTXAugust 10, 2026
Reuters
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MLTX

Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MLTXAugust 3, 2026
Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MLTX

Zacks Investment Research
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
MLTXJuly 31, 2026
Zacks Investment Research
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
MLTX

Stocktwits
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
MLTXJuly 13, 2026
Stocktwits
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
MLTX

The Motley Fool
MoonLake Immunotherapeutics' CFO Sells 39K Shares
MLTXJuly 3, 2026
The Motley Fool
MoonLake Immunotherapeutics' CFO Sells 39K Shares
MLTX

The Motley Fool
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
MLTXJune 24, 2026
The Motley Fool
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
MLTX

Stocktwits
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
MLTXJune 22, 2026
Stocktwits
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
MLTX

Stocktwits
S&P 500, Nasdaq, Dow Futures Slip After Trump Warns Iran Of Fresh Strikes Over Hormuz Standoff: INTC, MLTX, SNDK, KEEL In Focus
MLTXJune 22, 2026
Stocktwits
S&P 500, Nasdaq, Dow Futures Slip After Trump Warns Iran Of Fresh Strikes Over Hormuz Standoff: INTC, MLTX, SNDK, KEEL In Focus
MLTX
About MoonLake Immunotherapeutics Class A Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees130
CEODr. Jorge Santos da Silva Ph.D.
IPO DateOct 20, 2020
HeadquartersZug, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 1977 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 1988 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 1966 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | — |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | — |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | — |
| Joana Cortez | Associate Vice-President of Legal & Compliance | — |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | — |
| Luciana Marques | Associate Vice-President of HR, People and Culture | — |
| Ms. Nuala Brennan | Chief Clinical Development Officer | — |
Fundamentals
Valuation
Price-to-book value2.80
Profitability
Return on Equity-83.00%
Return on Assets-59.00%
EBITDA$-250.82M
Trading
Average volume1,637,376
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 63.33
- MACD 12/26/9
- 0.19
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.25
- SMA 50
- $11.98
- Price above SMA 50
- EMA 50
- $12.51
- Price above EMA 50
- SMA 200
- $16.29
- Price below SMA 200
- EMA 200
- $14.89
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $50.00
- Average
- $50.00
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -49.4 | +31.0 | -30.0 | +12.1 | +15.1 | -7.1 | +3.6 | +24.1 | +5.0 | |||
| 2023 | +8.3 | +57.2 | +7.0 | +3.3 | +19.9 | +85.1 | +19.9 | -0.5 | +5.7 | -10.0 | -9.6 | +31.0 |
| 2024 | -6.2 | -15.4 | -1.4 | -15.8 | -5.1 | +4.7 | -0.4 | +11.3 | +8.9 | -10.2 | +16.4 | -2.4 |
| 2025 | -14.1 | -4.3 | -1.6 | +15.8 | -5.9 | +14.7 | +8.2 | +5.3 | -87.8 | +43.1 | +34.6 | -0.5 |
| 2026 | +31.1 | +10.9 | +5.4 | -0.8 | +14.6 | +3.5 | -3.6 | -13.5 | -22.7 | +2.7 | +17.8 |
Compare stocks
Market cap
$1.15B
-
-
-
Price / Earnings ratio
-3.90
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,637,376
-
-
-
Earnings per share
$-3.67
-
-
-



